Anti-platelet therapy: ADP receptor antagonists

被引：85
作者：
Wijeyeratne, Yanushi Dullewe [1 ]
Heptinstall, Stan [1 ]
机构：
[1] Univ Nottingham, Div Cardiovasc Med, Sch Clin Sci, Queens Med Ctr, Nottingham NG7 2UH, England
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 72卷 / 04期
关键词：
anti-platelet; cangrelor; clopidogrel; platelet; P2Y12; prasugrel; ticagrelor; ACUTE CORONARY SYNDROMES; PLATELET-FUNCTION; P2Y(12) RECEPTOR; ADENOSINE-DIPHOSPHATE; ANTITHROMBOTIC AGENTS; DOSE CLOPIDOGREL; P2; RECEPTORS; HUMAN BLOOD; INHIBITION; AGGREGATION;
D O I：
10.1111/j.1365-2125.2011.03999.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function.
引用
收藏
页码：647 / 657
页数：11
相关论文
共 50 条
  • [41] Increased platelet reactivity in dyslipidemic patients with coronary artery disease on dual anti-platelet therapy
    Jaeger, Bernhard
    Piackova, Editha
    Haller, Paul Michael
    Andric, Tijana
    Kahl, Beatrice
    Christ, Guenther
    Geppert, Alexander
    Wojta, Johann
    Huber, Kurt
    ARCHIVES OF MEDICAL SCIENCE, 2019, 15 (01) : 65 - 71
  • [42] Platelet activation by ADP: the role of ADP antagonists
    Gachet, C
    ANNALS OF MEDICINE, 2000, 32 : 15 - 20
  • [43] Evidence with antiplatelet therapy and ADP-receptor antagonists
    Easton, JD
    CEREBROVASCULAR DISEASES, 2003, 16 : 20 - 26
  • [44] Anti-platelet and anti-coagulant therapy in peripheral arterial disease prior to surgical intervention
    Harky, Amer
    Maskell, Perry
    Burgess, Mika
    VASCULAR, 2019, 27 (03) : 299 - 311
  • [45] Spontaneous hematoma in the setting of dual anti-platelet therapy with ticagrelor: A case report
    Feng, Chunguang
    Wang, Linguang
    Wang, Lulu
    ONCOLOGY LETTERS, 2016, 12 (01) : 144 - 146
  • [46] Toll-like receptor 9 expression and activation in acute coronary syndrome patients on dual anti-platelet therapy
    Hally, Kathryn E.
    La Flamme, Anne C.
    Larsen, Peter D.
    Harding, Scott A.
    THROMBOSIS RESEARCH, 2016, 148 : 89 - 95
  • [47] Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?
    Christina G Perry
    Alan R Shuldiner
    Journal of Human Genetics, 2013, 58 : 339 - 345
  • [48] Why have studies of tailored anti-platelet therapy failed so far?
    Siller-Matula, Jolanta M.
    Jilma, Bernd
    THROMBOSIS AND HAEMOSTASIS, 2013, 110 (04) : 628 - 631
  • [49] Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?
    Perry, Christina G.
    Shuldiner, Alan R.
    JOURNAL OF HUMAN GENETICS, 2013, 58 (06) : 339 - 345
  • [50] ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease
    Gassanov, N.
    Caglayan, E.
    Erdmann, E.
    Er, F.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (27) : 1433 - 1437
12345